Biocompatible Glycoconjugation Enables Sensitive In Vivo Cell Tracking by PET/CT.

Authors

Nathan Clemons, Anna S Thickens, Liudmila Lambert Lepesevich, Zachary T Rosenkrans, Victor Santoro-Fernandes, Anatoly N Pinchuk, Eduardo Aluicio-Sarduy, Jason C Mixdorf, Saritha S D'Souza, Johnathan Caldon, John Kink, Matthew H Forsberg, Peiman Hematti, Jonathan W Engle, Igor Slukvin, Christian M Capitini, Reinier Hernandez

Published in

Journal of medicinal chemistry. Jun 24, 2026. Epub Jun 24, 2026.

Abstract

Cell-based therapies have transformed the treatment landscape for cancer, yet their clinical translation remains limited by unpredictable in vivo behavior and variable patient responses. Accurate, noninvasive image-based tracking of therapeutic cells, such as PET/CT, is essential for understanding biodistribution, improving safety, and optimizing the design of next-generation treatments. However, existing radiolabeling strategies for cell tracking using PET/CT lack the stability and sensitivity required for reliable long-term imaging. Here, we present a direct radiolabeling strategy that oxidizes cell surface sialic acids to conjugate aminooxy-DFO (AOD) and subsequently radiolabels cells with ⁸⁹Zr under biocompatible conditions. We radiolabeled five human and nonhuman primate immune cell types with high radiochemical incorporation (17-194 μCi per million cells) and purity (∼90%), while preserving cell viability. Serial PET/CT imaging over 7-8 days revealed conserved biodistribution patterns across all cell types tested. This approach provides a robust, applicable platform for longitudinal PET/CT tracking of therapeutic cells.

PMID:
42340745
Bibliographic data and abstract were imported from PubMed on 24 Jun 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.